Comparative analysis of drug resistance between serpatinib and platinib

Selpatinib and platinib, two importantRET inhibitors, have shown significant efficacy in the treatment of non-small cell lung cancer and thyroid cancer. However, with the widespread use of drugs, the problem of drug resistance has gradually become prominent and has become a key factor affecting the effectiveness of treatment.

Studies have shown that serpatinib resistance may be related to secondary mutations in the target gene. These mutations may change how the drug binds to its target, causing the drug to become ineffective. In addition, activation of bypass signaling is also an important mechanism of resistance to serpatinib, and cancer cells may bypass the inhibitory effect of the drug by activating other kinases or growth factor pathways.

Platinib resistance is also closely related to gene mutations, especially mutations in key genes such as EGFR, RET, and KRAS. These mutations may lead to a reduction in the lethal effect of the drug on cancer cells. In addition, platinib may also face the challenge of cancer cells reducing intracellular drug concentrations by increasing the expression of drug pumps, another common drug resistance mechanism.

Solutions to serpatinib resistance mainly include combination therapy and the development of new generation drugs. Combination drugs can overcome resistance to a single drug by inhibiting multiple targets simultaneously, while the development of next-generation drugs focuses on finding new compounds that can inhibit drug-resistant mutants more effectively.

Scientists are also exploring similar strategies for platinib resistance, including developing new drugs and combination treatments that target specific resistance mutations. In addition, in-depth study of the specific mechanisms of drug resistance in order to formulate treatment strategies more accurately is also an important direction of current research.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC8144197/